Fluticasone propionate and fluticasone propionate/salmeterol multidose dry powder inhalers compared with placebo for persistent asthma

Sher, Lawrence; Yiu, Gloria; Sakov, Anat; Liu, Siyu; Caracta, Cynthia

doi:10.2500/aap.2017.38.4069

Cited by 10 publications

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These values differ from the reports of drug efficacy, which evaluated its outcomes in a short time (twelve weeks); these studies showed an increase in FEV 1 >15% with the use of ICS/LABA. 28 , 29 A similar change was identified in the AG from t0 to t1, and after this time, it did not change significantly. Specifically, in the context of N-ERD, most studies have evaluated the beneficial role of desensitization.…”

Section: Discussionsupporting

confidence: 68%

Lung Function and Asthma Clinical Control in N-ERD Patients, Three-Year Follow-Up in the Context of Real-World Evidence

Pavón-Romero,

Falfán-Valencia,

Gutiérrez-Quiroz

et al. 2023

JAA

View full text Add to dashboard Cite

Purpose To describe the lung function and clinical control of asthma in patients with N-ERD during three years of medical follow-up using GINA guidelines. Methods We evaluated 75 N-ERD and 68 asthma patients (AG). Clinical control, lung function, and asthma treatment were evaluated according to GINA-2014. We compared all variables at baseline and one, two, and three years after treatment. Results At baseline, the N-ERD group had better basal lung function (LF) than the AG group ( p <0.01), and the AG group used higher doses of inhaled corticosteroids than the N-ERD group (52.4% vs 30.5%, p =0.01) and short-term oral corticosteroid (OCS) use (52.4% vs 30.5%, p <0.01). Instead, N-ERD patients needed more use of leukotriene receptor antagonists (LTRA) (29.3% vs 5.9%, p <0.01). This group had better clinical control than the AG group (62.1% vs 34.1%, p <0.01). During the medical follow-up, the LF of the N-ERD group remained at normal values; however, these parameters improved in AG from one year ( p <0.01). Likewise, there was a diminished use of high doses of ICS (52.4% vs 33%, p <0.05) and short-term OCS (67.6% vs 20.6%, p <0.01) in asthma patients. However, N-ERD patients still needed more use of LTRAs ( p <0.02) during the study. In this context, one-third of N-ERD patients had to use a combination of two drugs to maintain this control. From the second year on, clinical control of asthma was similar in both groups ( p >0.05). Conclusion According to GINA guidelines, only one-third of patients with N-ERD can gradually achieve adequate lung function and good asthma control with a high ICS dosage. Only a very small portion of patients will require the continued use of a second medication as an LTRA to keep their asthma under control.

show abstract

Section: Discussionsupporting

confidence: 68%

Lung Function and Asthma Clinical Control in N-ERD Patients, Three-Year Follow-Up in the Context of Real-World Evidence

Pavón-Romero,

Falfán-Valencia,

Gutiérrez-Quiroz

et al. 2023

JAA

View full text Add to dashboard Cite

show abstract

“…The database searches yielded 1109 unique publications and six records were identified through other sources (Figure 1). Overall, 27 publications that described the results from 19 unique studies [37,38,[49][50][51][52][53][54][55][56][57][58][59][60][61][62][63][64][65][66][67][68] were included in the SLR, of which 15 studies [37,38, 49,50,52-55, 57-62, 55-68] were deemed suitable for inclusion in the base case NMA (Table 2).…”

Section: Search Results and Study Characteristicsmentioning

confidence: 99%

Impact of inhaled fluticasone propionate/salmeterol on health-related quality of life in asthma: A network meta-analysis

Maneechotesuwan¹,

Singh²,

Fritscher³

et al. 2022

Respiratory Medicine

View full text Add to dashboard Cite

“…In the first trial, Sher et al 8 evaluated the efficacy and safety of fluticasone propionate and fluticasone propionate/salmeterol multidose dry powder inhalers compared with placebo for persistent asthma. In the second trial, Vanderwalker et al 9 evaluated the efficacy and safety of beclomethasone dipropionate breath-actuated or metered-dose inhaler in pediatric patients with asthma.…”

mentioning

confidence: 99%

Primum adiuvare … primum non nocere … and the practice of allergy

Bellanti¹,

Settipane²

2017

allergy asthma proc

View full text Add to dashboard Cite

Fluticasone propionate and fluticasone propionate/salmeterol multidose dry powder inhalers compared with placebo for persistent asthma

Abstract: Delivery of Fp and FS via the novel MDPI provided significant clinical benefits and was well tolerated in patients with persistent asthma.

Cited by 10 publications

References 3 publications

Lung Function and Asthma Clinical Control in N-ERD Patients, Three-Year Follow-Up in the Context of Real-World Evidence

Lung Function and Asthma Clinical Control in N-ERD Patients, Three-Year Follow-Up in the Context of Real-World Evidence

Impact of inhaled fluticasone propionate/salmeterol on health-related quality of life in asthma: A network meta-analysis

Primum adiuvare … primum non nocere … and the practice of allergy

Contact Info

Product

Resources

About